Analog series were systematically extracted from more than 650 000 bioactive compounds originating from medicinal chemistry and screening sources and more than 3.6 million commercial compounds that were not biologically annotated. Then, analog series-based (ASB) scaffolds were generated. For each scaffold from a bioactive series, a target profile was derived and ASB scaffolds shared by bioactive and commercial compounds were determined. On the basis of our analysis, large segments of commercial chemical space were not yet explored biologically. Shared ASB scaffolds established structural relationships between bioactive and commercial chemical space, and the target profiles of these scaffolds were transferred to commercially available analogs of active compounds. This made it possible to derive target hypotheses for more than 37 000 compounds without biological annotations covering more than 1000 different targets. For many molecules, alternative target assignments were available. Target hypotheses for these compounds should be of interest, for example, for hit expansion, acquisition of compounds to design or further extend focused libraries for drug discovery, or testing of expanded analog series on different targets. They can also be used to search for analogs and complement compound series during target-directed optimization. Therefore, all of the commercial molecules with new target hypotheses as well as key scaffolds identified in our analysis and their target profiles are made freely available.

Exploring structural relationships between bioactive and commercial chemical space and developing target hypotheses for compound acquisition

Cerchia, Carmen;Lavecchia, Antonio
Penultimo
;
2017

Abstract

Analog series were systematically extracted from more than 650 000 bioactive compounds originating from medicinal chemistry and screening sources and more than 3.6 million commercial compounds that were not biologically annotated. Then, analog series-based (ASB) scaffolds were generated. For each scaffold from a bioactive series, a target profile was derived and ASB scaffolds shared by bioactive and commercial compounds were determined. On the basis of our analysis, large segments of commercial chemical space were not yet explored biologically. Shared ASB scaffolds established structural relationships between bioactive and commercial chemical space, and the target profiles of these scaffolds were transferred to commercially available analogs of active compounds. This made it possible to derive target hypotheses for more than 37 000 compounds without biological annotations covering more than 1000 different targets. For many molecules, alternative target assignments were available. Target hypotheses for these compounds should be of interest, for example, for hit expansion, acquisition of compounds to design or further extend focused libraries for drug discovery, or testing of expanded analog series on different targets. They can also be used to search for analogs and complement compound series during target-directed optimization. Therefore, all of the commercial molecules with new target hypotheses as well as key scaffolds identified in our analysis and their target profiles are made freely available.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/721748
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact